FGF23 and chronic kidney disease: Clinical studies, both in pre-dialysis CKD and in dialysis patients, confirm the positive correlation between Sclerostin and FGF23 [18], and a direct correlation has been demonstrated also as bone expression, in a study involving pediatric patients with different types of solid organ allografts (22 patients in total, only 8 KTR) [30].